Junshi Bio (01877) announced that Teripulidumab (European commodity name: LOQTORZI) ...
Junshi Bio (01877) announced that the application for the marketing authorization of Teripulidumab (European commodity name: LOQTORZI) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending its approval for two indications: Teripulidumab combined with cisplatin and gemcitabine for first-line treatment of recurrent, unresectable or metastatic nasopharyngeal carcinoma in adults who are not suitable for curative treatment with surgery or radiotherapy, and Teripulidumab combined with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma in adults. The European Commission will take into account the positive opinion of CHMP in order to make the final approval decision for Teripulidumab's marketing authorization application.